As afatinib is a substrate for the P-glycoprotein ( P-gp ) pump transporter the three studies presented here investigated the pharmacokinetics of afatinib in the presence of a potent inhibitor ( ritonavir ) or inducer [ rifampicin ( rifampin ) ] of P-gp .